FibroBiologics (FBLG) to Release Earnings on Wednesday

FibroBiologics (NASDAQ:FBLG) is expected to release its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect FibroBiologics to post earnings of ($1.3340) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, April 30, 2026 at 7:00 AM ET.

FibroBiologics (NASDAQ:FBLG) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.33) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.33). On average, analysts expect FibroBiologics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

FibroBiologics Stock Performance

NASDAQ:FBLG opened at $1.33 on Wednesday. The stock has a fifty day moving average of $3.82 and a 200 day moving average of $5.39. FibroBiologics has a 52-week low of $1.03 and a 52-week high of $22.60. The firm has a market capitalization of $4.67 million, a price-to-earnings ratio of -0.19 and a beta of 1.16.

Analyst Ratings Changes

A number of equities analysts recently weighed in on FBLG shares. Maxim Group cut FibroBiologics from a “buy” rating to a “hold” rating in a report on Monday. D. Boral Capital reiterated a “hold” rating on shares of FibroBiologics in a report on Thursday, March 26th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target (up from $4.00) on shares of FibroBiologics in a research note on Thursday, April 16th. Wall Street Zen raised FibroBiologics to a “sell” rating in a research note on Saturday, April 4th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of FibroBiologics in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $74.00.

Insider Buying and Selling at FibroBiologics

In related news, CFO Jason Davis purchased 3,500 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were bought at an average price of $8.20 per share, for a total transaction of $28,700.00. Following the purchase, the chief financial officer directly owned 3,500 shares of the company’s stock, valued at approximately $28,700. This represents a ? increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders purchased 9,574 shares of company stock valued at $72,886. Corporate insiders own 13.00% of the company’s stock.

Institutional Trading of FibroBiologics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC purchased a new stake in shares of FibroBiologics in the 4th quarter worth approximately $34,000. Renaissance Technologies LLC lifted its holdings in shares of FibroBiologics by 287.3% during the 4th quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock valued at $52,000 after buying an additional 171,800 shares during the period. Geode Capital Management LLC lifted its holdings in shares of FibroBiologics by 20.7% during the 4th quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock valued at $78,000 after buying an additional 59,813 shares during the period. Landscape Capital Management L.L.C. bought a new position in shares of FibroBiologics during the 3rd quarter valued at $191,000. Finally, Cerity Partners LLC increased its stake in shares of FibroBiologics by 37.2% in the 2nd quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock worth $80,000 after purchasing an additional 34,702 shares in the last quarter.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.